Enter inventor name

Patrick Rene Angibaud

This inventor holds 30 USPTO granted patents and 4 published patent applications, plus 35 CIPO patents, primarily in Cancer Therapeutics. Top assignees: Janssen Pharmaceutica Nv, Astex Therapeutics Limited, Janssen-Cilag S.a.. Active years: 1999-2024.

USPTO Granted Patents = 30 (Patent Applications = 4)

% Patents Active = 90.0

CIPO Patents = 35 (Patent Applications = 8)

Average Co-Inventor Count = 5.7

ph-index = 9

Forward Citations = 259(Granted Patents)

Location History:

Fontaine-Bellinger, FR (2017)
Fontaine-Bellenger, FR (1999 - 2018)
Issy-les-Moulineaux, FR (2021)
Saint Pierre d'Autils, FR (2018 - 2024)

Company Filing History:

24 out of 2,100

Janssen Pharmaceutica Nv

patents

5 out of 126

Astex Therapeutics Limited

Years Active: 1999-2024

Loading Chart...

Areas of Expertise:

Menin-MLL Interaction

PI3K Inhibitors

Histone Deacetylase

FGFR Kinase

Bicyclic Compounds

Quinoxaline Derivatives

Farnesyltransferase

Tetrahydrophenanthridinones

Substituted Indolyl Derivatives

Pyridine Derivatives

Bi-heteroaryl Benzodiazepines

Azepane Inhibitors

30 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12084462 - Spiro bicyclic inhibitors of menin-MLL interaction (2024-09-10),

2. 11542247 - Bi-heteroaryl substitute 1,4-benzodiazepines and uses thereof for the treatment of cancer (2023-01-03),

3. 11530226 - Azepane inhibitors of menin-MLL interaction (2022-12-20),

4. 11267804 - (R)-8-(1-((3-fluorophenyl)amino)ethyl)-N-(2-hydroxyethyl)-2-morpholinoquinoxaline-6-carboxamide for inhibiting phosphoinositide-3-kinase activity (2022-03-08),

5. 11220517 - Spiro bicyclic inhibitors of menin-MLL interaction (2022-01-11),

6. 11155555 - Compounds (2021-10-26),

7. 10975100 - Fused bicyclic inhibitors of menin-MLL interaction (2021-04-13),

8. 10894793 - Bicyclic pyridine, pyrazine, and pyrimidine derivatives as PI3K beta inhibitors (2021-01-19),

9. 10611778 - Fused bicyclic inhibitors of menin-MLL interaction (2020-04-07),

10. 10526316 - Quinoxaline and pyridopyrazine derivatives as PI3Kβ inhibitors (2020-01-07),

11. 10202387 - Heterocyclyl linked imidazopyridazine derivatives as PI3KB inhibitors (2019-02-12),

12. 10087187 - Imidazopyridazine derivatives as PI3KB inhibitors (2018-10-02),

13. 10045982 - Substituted pyrido[2,3-b]pyrazines as FGFR kinase inhibitors (2018-08-14),

14. 9636341 - Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase (2017-05-02),

15. 9598396 - Tetrahydrophenanthridinones and tetrahydrocyclopentaquinolinones as PARP and tubulin polymerization inhibitors (2017-03-21),

Title: **Patrick Rene Angibaud: Innovator in Pharmaceutical Chemistry**

Introduction

Patrick Rene Angibaud is a prominent inventor based in Fontaine-Bellenger, France. With a remarkable portfolio of 30 patents, he has made significant contributions to the field of pharmaceutical chemistry, particularly in developing innovative therapeutic agents.

Latest Patents

Among his latest inventions are spiro bicyclic inhibitors of the menin-MLL interaction, which are pharmaceutical agents designed for therapy and prophylaxis in mammals. These compounds show promise in treating critical diseases such as cancer, myelodysplastic syndrome (MDS), and diabetes. Another notable patent pertains to bi-heteroaryl substituted 1,4-benzodiazepines, which involve new derivative compounds that have potential applications in cancer treatment. These innovations not only enhance the existing therapies but also open doors for new treatments in oncology.

Career Highlights

Patrick has worked with leading companies in the pharmaceutical industry, including Janssen Pharmaceutica NV and Astex Therapeutics Limited. His experience in these organizations has allowed him to push the boundaries of drug development and contribute to meaningful advancements in medicine.

Collaborations

Throughout his career, Patrick has collaborated with notable colleagues such as Olivier Alexis Georges Querolle and Lieven Meerpoel. These collaborations have enriched his work and led to the creation of groundbreaking solutions in drug discovery.

Conclusion

Patrick Rene Angibaud's innovative approach and dedication to pharmaceutical research have resulted in critical advancements in therapeutic agents. His work continues to impact the medical field, offering hope for new and effective treatments for various diseases.

Profile summary based on public USPTO records.

Please report any incorrect information to [email protected]